Assembly Biosciences, Inc.
$28.13
▼
-1.43%
2026-04-21 05:25:01
www.assemblybio.com
NMS: ASMB
Explore Assembly Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$446.22 M
Current Price
$28.13
52W High / Low
$39.7 / $9.68
Stock P/E
—
Book Value
$13.04
Dividend Yield
—
ROCE
-5.8%
ROE
-5.1%
Face Value
—
EPS
$-0.55
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
73
Beta
1.16
Debt / Equity
1.27
Current Ratio
5.22
Quick Ratio
5.22
Forward P/E
-12.3
Price / Sales
6.24
Enterprise Value
$205.34 M
EV / EBITDA
-17.13
EV / Revenue
2.84
Rating
Strong Buy
Target Price
$48.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 2. | Sarepta Therapeutics, Inc. | $21.42 | — | $2.24 B | — | -29.18% | -53.47% | $64.8 / $10.42 | $10.87 |
| 3. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
| 4. | Intellia Therapeutics, Inc. | $15.21 | — | $1.8 B | — | -59.74% | -53.48% | $28.25 / $6.8 | $5.77 |
| 5. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 6. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 7. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 42.47 M | 10.79 M | 9.63 M | 9.42 M | 7.36 M | — |
| Operating Profit | 19.8 M | -10.88 M | -11.09 M | -9.94 M | -11.53 M | — |
| Net Profit | 22.09 M | -9.2 M | -10.2 M | -8.82 M | -10.34 M | — |
| EPS in Rs | 1.39 | -0.58 | -0.64 | -0.56 | -0.65 | -1.51 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 72.3 M | 28.52 M | 7.16 M | 0 M |
| Operating Profit | -12.12 M | -45.42 M | -64.65 M | -94.11 M |
| Net Profit | -6.12 M | -40.18 M | -61.23 M | -93.09 M |
| EPS in Rs | -0.39 | -2.53 | -3.86 | -5.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 257.59 M | 119.17 M | 136.82 M | 101.79 M |
| Total Liabilities | 50.84 M | 85.81 M | 95.73 M | 19.13 M |
| Equity | 206.75 M | 33.36 M | 41.1 M | 82.66 M |
| Current Assets | 254.55 M | 115.5 M | 133.79 M | 96.97 M |
| Current Liabilities | 48.78 M | 47.8 M | 39.23 M | 16.3 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -41.09 M | -51.12 M | 22.74 M | -84.46 M |
| Investing CF | -113.47 M | 40.17 M | -69.14 M | 90.64 M |
| Financing CF | 174.67 M | 29.45 M | 13.82 M | 0.61 M |
| Free CF | -41.16 M | -51.15 M | 22.49 M | -84.56 M |
| Capex | -0.07 M | -0.03 M | -0.26 M | -0.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 298.16% | — | — | — |
| Earnings Growth % | 34.38% | 34.23% | — | — |
| Profit Margin % | -140.87% | -854.78% | — | — |
| Operating Margin % | -159.26% | -902.5% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -158.8% | -896.22% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-02-12 | 1:0.0833333 |